Press Releases

 
Press Releases
  Date Title and Summary View
Aug 15, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the pricing of its previously announce...
Aug 14, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced an agreement to sell 2,500,000 ordinar...
Aug 1, 2017
Second quarter revenue of $26.1 million, an increase of 36% compared to prior year periodContinued growth from both the Tuberculosis and Tick-borne disease franchisesSuccessful negotiation of a settlement with Statens Serum Institut which will result in substantial future gross margin im...
Jul 24, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Richard Wenstrup, M...
Jul 18, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release sec...
Jun 22, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of...
Jun 15, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a favorable Markman claim...
Jun 5, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the appointment of Karen ...
May 2, 2017
First quarter revenue of $21.5 million, an increase of 26% compared to prior year periodFirst quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year periodFirst quarter Tick-borne disease and other revenue of $3.0 million OXFORD, United Kingd...
Apr 19, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to relea...
Page:
1
... NextLast
= add release to Briefcase